Neuraxis Inc
Research Neuraxis Inc (NRXS) on Bullrun: market cap USD 75.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNRXS
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 75.31M
- Financial periodQ1 2026
- RevenueUSD 1.61M
- Net income-USD 1.76M
- Free cash flow-USD 1.23M
- Gross margin86.4%
Valuation Snapshot
latest market cap is USD 75.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.57M | -USD 7.80M | -USD 6.46M | 84.2% | -0.95 | USD 4.97M | USD 148.29K | USD 3.40M |
| FY2024 | USD 2.69M | -USD 8.24M | -USD 6.13M | 86.5% | -1.22 | USD 3.70M | USD 154.15K | USD 2.07M |
| FY2023 | USD 2.46M | -USD 14.63M | -USD 6.72M | 87.7% | -4.5 | USD 78.56K | USD 148.06K | -USD 1.40M |
| FY2022 | USD 2.68M | -USD 4.78M | -USD 2.30M | 88.9% | -2.77 | USD 253.70K | USD 228.34K | -USD 5.57M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 75.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 48.36M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 16.43M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 14.12M | n/a | n/a | n/a |
About Neuraxis Inc
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neuraxis Inc's market cap?
Neuraxis Inc's market capitalization is USD 75.31M.
What does Neuraxis Inc do?
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders.